Skip to main content

Table 6 Overview of the embryological outcome from the cycles before SARS-CoV-2 infection from the same patient

From: Effects of SARS-CoV-2 infection on embryological outcomes in assisted reproductive technology during the Omicron epidemic

Patient

cycle number

SARS-CoV-2 infection

protocols for ovarian stimulation

Fertilization method

Fertilization rate (%)

Oocyte maturity rate (%)

2PN rate (%)

D3 available embryos rate (%)

D3 good-quality embryos rate (%)

Blastocyst formation rate (%)

Good-quality blastocyst formation rate (%)

 

1

1

No

Ultra-long

IVF

66.67% (4/6)

N/A

16.67% (1/6)

0 (0/1)

0 (0/1)

N/A

N/A

 

1

2

No

Long-acting long

IVF

0%(0/16)

N/A

N/A

N/A

N/A

N/A

N/A

 

1

3

No

Antagonist

ICSI

100%(3/3)

100% (3/3)

100% (3/3)

66.67% (2/3)

33.33% (1/3)

N/A

N/A

 

1

4

Yes

Mini-stimulation

ICSI

66.67% (2/3)

37.5% (3/8)

66.67% (2/3)

66.67% (2/3)

50% (1/2)

N/A

N/A

 

2

1

No

Long-acting long

IVF

77.27% (17/22)

N/A

63.64% (14/22)

82.35% (14/17)

50% (7/14)

50% (7/14)

35.71% (5/14)

 

2

2

Yes

Antagonist

IVF

83.33% (10/12)

N/A

33.33% (4/12)

50% (5/10)

25% (1/4)

0 (0/8)

0 (0/8)

 

3

1

No

Antagonist

IVF

33.33% (5/15)

N/A

26.67% (4/15)

80% (4/5)

25% (1/4)

33.33% (1/3)

33.33% (1/3)

 

3

2

Yes

Antagonist

IVF

68.42% (13/19)*

N/A

57.89% (11/19)

53.85% (7/13)

18.18% (2/11)

31.5% (3/8)

12.5% (1/8)

 

4

1

No

Antagonist

IVF

70% (7/10)

N/A

60% (6/10)

42.86% (3/7)

50% (3/6)

50% (3/6)

33.33% (2/6)

 

4

2

No

Long-acting long

IVF

46.15% (6/13)

N/A

30.77% (4/13)

16.67% (1/6)

0 (0/4)

0 (0/3)

0 (0/3)

 

4

3

Yes

Antagonist

ICSI

60% (3/5)

100% (5/5)

40% (2/5)

33.33% (1/3)

0 (0/2)

50% (1/2)

0 (0/2)

 

5

1

No

Antagonist

IVF

50% (7/14)

N/A

28.57% (4/14)

42.86% (3/7)

0 (0/4)

50% (1/2)

50% (1/2)

 

5

2

Yes

Antagonist

IVF

90% (9/10)*

N/A

90% (9/10)*

88.89% (8/9)*

66.67% (6/9)*

42.86% (3/7)

28.57% (2/7)

 

6

1

No

Antagonist

ICSI

66.67% (6/9)

75% (9/12)

66.67% (6/9)

100% (6/6)

50% (3/6)

33.33% (2/6)

16.67% (1/6)

 

6

2

Yes

Long-acting long

ICSI

44.44% (4/9)

81.82% (9/11)

44.44% (4/9)

50% (2/4)

25% (1/4)

50% (2/4)

25% (1/4)

 

7

1

No

Mini-stimulation

IVF

100% (1/1)

N/A

0 (0/1)

0 (0/1)

− (0/0)

0(0/1)

0 (0/1)

 

7

2

Yes

Mini-stimulation

IVF

50% (2/4)

N/A

50% (2/4)

50% (1/2)

50% (1/2)

0(0/1)

0 (0/1)

 
  1. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; 2PN, 2 pronucleus; D3, day 3; IVF, in-vitro fertilization; ICSI, intracytoplasmic sperm injection
  2. *The embryological outcome of the same patient was statistically different in different cycles
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us